Toxoplasma gondii-derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide

• DOI: 10.1007/s12032-023-01994-y
• Publication Date: 2023-04-04T12:23:43Z
• Authors: Cherine A. Ismail; Maha M. Eissa; Maha R. Gaafar; Layla K. Younis; Nahla El Skhawy
• Keywords: Immunobiology of Dendritic Cells; Immunology; Toxoplasma gondii; Antineoplastic Agents; Cancer research; CD8-Positive T-Lymphocytes; Tumor cells; Cancer Vaccines; Mice; Adjuvants, Immunologic; Biochemistry, Genetics and Molecular Biology; Tumor Microenvironment; Animals; Chemotherapy; Molecular Biology; Cyclophosphamide; Biology; Internal medicine; Antibody; Cancer; Immunology and Microbiology; Tumor Targeting; Original Paper; Solid tumor; FOS: Clinical medicine; Mechanisms and Applications of RNA Interference; Carcinoma; Life Sciences; Hematology; Engineering Bacteria for Cancer Treatment; 3. Good health; Disease Models, Animal; Immune system; Tumor microenvironment; Antigen; Medicine; Immunotherapy; Toxoplasma; Biotechnology

AbstractPathogen-based cancer vaccine is a promising immunotherapeutic weapon to stimulate cancer immunosuppressive state. Toxoplasma gondii is a potent immunostimulant, and low-dose infection was linked to cancer resistance. Our goal was to evaluate the therapeutic antineoplastic activity of autoclaved Toxoplasma vaccine (ATV) against Ehrlich solid carcinoma (ESC) in mice in reference to and in combination with low-dose cyclophosphamide (CP), a cancer immunomodulator. Mice inoculation with ESC was followed by applying different treatment modalities including ATV, CP, and CP/ATV. We evaluated the impact of the different treatments on liver enzymes and pathology, tumor weight, volume, and histopathological changes. Using immunohistochemistry, we evaluated CD8+ T cell, FOXP3+ Treg, CD8+/Treg outside and inside ESC, and angiogenesis. Results showed significant tumor weights and volumes reduction with all treatments with 13.3% inhibition of tumor development upon combined CP/ATV use. Significant necrosis and fibrosis were noted in ESC by all treatments with improved hepatic functions versus non-treated control. Although ATV was almost equivalent to CP in tumor gross and histopathology, it promoted an immunostimulatory activity with significant Treg cells depletion outside ESC and CD8+ T cells infiltration inside ESC with higher CD8+ T/Treg ratio inside ESC superior to CP. Combined with CP, ATV exhibited significant synergistic immunotherapeutic and antiangiogenic action compared to either treatment alone with significant Kupffer cells hyperplasia and hypertrophy. Exclusively, therapeutic antineoplastic and antiangiogenic activity of ATV against ESC was verified that boosted CP immunomodulatory action which highlights a novel biological cancer immunotherapeutic vaccine candidate.